Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.

Who May Be Eligible (Plain English)

Who May Qualify: - New diagnosis of HCC made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4) - Availability of a pre-therapeutic three-phase contrast-enhanced abdominal-pelvic CT scan. Non-Who May Qualify: - Presence of an active cancer other than HCC - Uncontrolled HIV infection. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * New diagnosis of HCC made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4) * Availability of a pre-therapeutic three-phase contrast-enhanced abdominal-pelvic CT scan. Non-inclusion criteria: * Presence of an active cancer other than HCC * Uncontrolled HIV infection.

Treatments Being Tested

OTHER

Dynamometry measurement, myokine dosing, sarcopenia calculation

Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index

Locations (1)

Damien JOLLY
Reims, France